Extended Data Fig. 3: Analysis of performance differences between MRI-PTPCa and clinical tools in prostate cancer diagnosis.
From: An MRI–pathology foundation model for noninvasive diagnosis and grading of prostate cancer
a) Distribution of PSA. For visualization purposes, PSA values > 40 ng/mL were capped at 40 ng/mL. The x-axis represents PSA values, and the y-axis represents the corresponding frequency. Q1 represents the cut-off point for the first 25% of the data points. Q3 represents the cut-off point for the first 75% of the data points. PSA here denotes total prostate specific antigen. b) ROC analysis of Improvement between PSA and MRI-PTPCa in PCa detection. c) ROC difference between PI-RADS and MRI-PTPCa in PCa detection based on PSA gray zone. Two-sided DeLong test was used to compare the AUCs of the ROC curves.
